Cameco Corporation · Energy
The price already needs more growth than analysts forecast, at both a 9% and an 8% discount rate.
Drowns: at a 23.0% margin the price needs +19.8% 3y revenue growth against +7.5% consensus, a -24.7pt cushion versus a 4pt correction cut. AI-power optionality priced in a contract business; dented, not broken.
Would recover if: The drowns call is wrong if consensus growth rises by more than 24.7pt or the margin proves well above 23.0%.. We re-check this against analyst estimates every evening.
10 years, at a 23% margin analysts expect
+5.5%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
7 published targets, set before the drop
Linked to AMZN, META, MSFT
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 266% of reported profit arrived as operating cash, so the analysts' margin stands.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 10, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits at the 14th percentile of the published analyst models, rejecting the four bull cases that project 28-37% upside, and instead endorsing the Barclays targets that assume the company's current growth rate does not accelerate.
The price assumes Cameco's current contract book and the existing uranium deficit, but refuses to pay for the revenue acceleration required to justify its high valuation; unit volume data can measure whether revenue is actually accelerating, but it cannot measure the uranium pricing or policy tailwinds that would drive it.
What the price refuses to pay for, and the full reconstruction, on the CCJ quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names